vida: extract claims from 2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks

- Source: inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures.md

@@ -24,3 +24,10 @@ A 2-person AI-staffed GLP-1 telehealth startup reached $1.8 billion in sales run
 **Source:** National Geographic 2025
 
 BMI 16 anorexia patient acquired GLP-1 online by lying about weight. Most patients receive NO eating disorder evaluation before prescription. Psychologist Robyn Pashby: clinicians must 'hold two truths' — efficacy for some, harm risk for others — but screening infrastructure absent.
+
+
+## Supporting Evidence
+
+**Source:** NPR Health, February 2026
+
+NPR Health (February 2026) confirms that GLP-1s are 'easy to obtain online, with little screening' and that 'most patients receive NO evaluation for eating disorders before prescription.' This documents the screening gap in online prescribing channels specifically, confirming that telehealth GLP-1 prescribing operates without the psychiatric screening that professional guidelines recommend.

domains/health/atypical-anorexia-creates-invisible-glp1-contraindication-through-normal-weight-presentation.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The highest-risk population for GLP-1 harm overlaps with the typical candidate appearance, creating systematic under-detection
+confidence: experimental
+source: NPR Health, February 2026, clinical expert interviews identifying atypical anorexia as 'at high risk of being harmed'
+created: 2026-05-04
+title: Atypical anorexia creates an invisible GLP-1 contraindication because patients maintain normal weight making restrictive eating disorders undetectable in standard prescribing workflows
+agent: vida
+sourced_from: health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md
+scope: functional
+sourcer: NPR Health
+supports: ["glp1-eating-disorder-screening-recommended-not-mandated-creating-structural-safety-gap"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+---
+
+# Atypical anorexia creates an invisible GLP-1 contraindication because patients maintain normal weight making restrictive eating disorders undetectable in standard prescribing workflows
+
+Clinicians identify atypical anorexics as the population 'at high risk of being harmed' by GLP-1s, but this population is structurally invisible in current prescribing workflows. Atypical anorexia is characterized by restrictive eating patterns and anorexia nervosa psychology but with maintained normal weight (unlike classic anorexia where low BMI is diagnostic). This creates a detection problem: GLP-1s are now prescribed primarily for weight management to patients who appear to have normal or elevated weight, which is exactly the presentation of atypical anorexia. Without systematic psychiatric screening (which as documented above essentially never happens), prescribers cannot distinguish between a patient seeking medically appropriate weight management and a patient with an undiagnosed restrictive eating disorder. The source notes that doctors 'may not recognize the condition' because the normal weight presentation doesn't trigger clinical suspicion. Given that GLP-1s 'suppress natural hunger cues more profoundly' than earlier drugs, prescribing them to patients who are already restricting food intake creates a pharmacological amplification of an existing pathology. This represents a case where the typical candidate appearance (normal or elevated weight seeking reduction) overlaps with the highest-risk contraindicated population (atypical anorexics with normal weight), making harm prevention dependent on screening infrastructure that doesn't exist.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: causal
 sourcer: MDPI Nutrients
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
 ---
 
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
@@ -24,3 +24,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou
 **Source:** PMC/Journal of Clinical Medicine systematic review, 2025
 
 2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.
+
+
+## Extending Evidence
+
+**Source:** NPR Health, February 2026
+
+Clinicians interviewed by NPR Health (February 2026) specifically identify atypical anorexics as 'at high risk of being harmed' by GLP-1s because they 'restrict food but maintain normal weight' making the condition difficult for doctors to recognize. This provides clinical expert confirmation of the restrictive subtype risk and identifies the detection problem: normal weight presentation in atypical anorexia overlaps with typical GLP-1 candidate appearance.

domains/health/glp1-eating-disorder-screening-recommended-not-mandated-creating-structural-safety-gap.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: The gap between pharmacovigilance signal detection and clinical practice intervention mirrors SDOH screening adoption failure
+confidence: experimental
+source: NPR Health, February 2026, interviews with Robyn Pashby (psychologist) and Samantha DeCaro (clinician)
+created: 2026-05-04
+title: GLP-1 eating disorder screening is recommended but essentially never practiced because no regulatory body mandates it and no reimbursement exists for the time required
+agent: vida
+sourced_from: health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md
+scope: structural
+sourcer: NPR Health
+related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+---
+
+# GLP-1 eating disorder screening is recommended but essentially never practiced because no regulatory body mandates it and no reimbursement exists for the time required
+
+Despite professional recommendations for eating disorder screening before GLP-1 prescription and documented pharmacovigilance signals (aROR 4.17-6.80 for eating disorders), most patients receive NO evaluation for eating disorders before prescription. The drugs are 'easy to obtain online, with little screening' according to clinicians interviewed. This represents a structural misalignment: the signal exists in pharmacovigilance data, professional guidelines recommend screening, but no regulatory body (FDA, CMS, state medical boards) mandates it, and no reimbursement mechanism exists for the time required to conduct proper psychiatric screening in primary care settings where most GLP-1s are prescribed. The result is that a known high-risk population (nearly 10% of Americans meet clinical eating disorder criteria at some point in their lives) receives a medication that 'suppresses natural hunger cues more profoundly' than earlier weight-loss drugs without any systematic screening to identify contraindicated patients. This mirrors the SDOH screening adoption failure documented in the KB: interventions that produce better outcomes but that no system rewards doing remain at negligible adoption rates despite evidence of benefit.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: structural
 sourcer: MDPI Nutrients
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
 ---
 
 # Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
@@ -24,3 +24,10 @@ This review provides detailed clinical recommendations for eating disorder risk
 **Source:** PMC/Journal of Clinical Medicine systematic review, 2025
 
 Review explicitly states 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders specifically, and calls for pre/post-treatment psychological assessment and screening for high-risk ED patients before initiating, but notes these are recommendations not requirements.
+
+
+## Extending Evidence
+
+**Source:** NPR Health, February 2026
+
+NPR Health (February 2026) reports that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and that drugs are 'easy to obtain online, with little screening.' This documents the gap between recommendation and practice at scale, not just as policy but as observed clinical reality. The source identifies no regulatory mandate from FDA, CMS, or state medical boards, and no reimbursement mechanism for the psychiatric screening time required in primary care settings where most GLP-1s are prescribed.

inbox/archive/health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md

@@ -7,10 +7,13 @@ date: 2026-02-04
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: high
 tags: [glp1, eating-disorders, anorexia, atypical-anorexia, screening-gaps, access, misuse]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content